As TP53 mutation is common in gastric cancer [57] and a driver mutation and frequent event (> 30%) in hepatic cancers [58], the combined targeting of mutant p53 with APR-246 and depletion of asparagine with ASNase may also be fruitful approach in some solid cancers with low ASNS expression. The gene discussed is TP53; the disease is gastric cancer.